uniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
Tweet Send to a Friend
uniQure (NASDAQ: QURE) Climbs ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
